@misc{10481/80524,
year = {2023},
month = {1},
url = {https://hdl.handle.net/10481/80524},
abstract = {Background: Brain-derived neurotrophic factor (BDNF), a neurotrophic
growth factor mainly expressed in the brain, has been proposed as a potential
effect biomarker; that is, as a measurable biomarker whose values could
be associated with several diseases, including neurological impairments. The
European Human Biomonitoring Initiative (HBM4EU) has also recognized
effect biomarkers as a useful tool for establishing link between exposure
to environmental pollutants and human health. Despite the well-establish
protocol for measuring serum BDNF, there is a need to validate its assessment
in urine, a non-invasive sample that can be easily repeated over time. The
aim of this study was to develop, standardize and validate a methodology to
quantify BDNF protein levels in urine samples before its implementation in
biomonitoring studies.
Methods: Different experimental conditions and non-competitive commercial
enzyme-linked immunosorbent assay (ELISA) kits were tested to determine
the optimal analytical procedure, trying to minimize the shortcomings of
ELISA kits. The fine-tune protocol was validated in a pilot study using both
upon awakening (n = 150) and prior to sleeping (n = 106) urine samples from the
same Spanish adolescent males in a well-characterized study population (the
Spanish INMA-Granada cohort).
Results: The best results were obtained in 0.6 ml of urine after the acidification
and extraction (pre-concentration) of samples. The highest reproducibility was
obtained with the ELISA kit from Raybiotech. Urinary BDNF concentrations of
adolescent males were within the previously reported range (morning = 0.047–
6.801 ng/ml and night = 0.047–7.404 ng/ml). Urinary BDNF levels in the
awakening and pre-sleep samples did not follow a normal distribution and
were not correlated. Conclusion: The developed methodology offers good sensitivity and reproducibility. Having reliable markers in urine may facilitate both diagnosis and monitoring possible diseases (and treatment). Further studies are needed to implement urinary BDNF in biomonitoring studies to further elucidate its usefulness and biological significance for neurological impairments.},
organization = {European Commission	733032},
organization = {Biomedical Research Networking Center-CIBER de Epidemiologia y Salud Publica (CIBERESP) of the Institute of Health Carlos III},
organization = {Institute of Health Carlos III (SCIII) - European Regional Development Fund/FEDER	FIS-PI17/01526
FIS-PI20/01656},
organization = {Instituto de Salud Carlos III	FI21/00236},
organization = {Miguel Servet Type II Program	CP1121/00014},
organization = {Spanish Government	FPU17/01848},
organization = {Junta de Andalucia-PAIDI (Spain)},
publisher = {Frontiers},
keywords = {BDNF},
keywords = {Validation},
keywords = {Urine},
keywords = {Effect biomarker},
keywords = {Human health},
title = {Development and validation of brain-derived neurotrophic factor measurement in human urine samples as a non-invasive effect biomarker},
doi = {10.3389/fnmol.2022.1075613},
author = {Olivas Martínez, Alicia and Suárez, Beatriz and Salamanca Fernández, Elena and Reina Pérez, Iris and Rodríguez Carrillo, Andrea and Mustieles Miralles, Vicente and Olea Serrano, Nicolás and Freire, Carmen and Fernández Cabrera, Mariana Fátima},
}